An antibody-drug conjugate with intracellular drug release properties showing specific cytotoxicity against CD7-positive cells.

Refractory T cell acute leukaemias that no longer respond to treatment would benefit from new modalities that target T cell-specific surface proteins. T cell associated surface proteins (the surfaceome) offer possible therapy targets to reduce tumour burden but also target the leukaemia-initiating cells from which tumours recur. Recent studies of the T cell leukaemia surfaceome confirmed that CD7 is highly expressed in overt disease. We have used an anti-CD7 antibody drug conjugate (ADC) to show that the binding of antibody to surface CD7 protein results in rapid internalization of the antigen together with the ADC. As a consequence, cell killing was observed via induction of apoptosis and was dependent on cell surface CD7. The in vitro cytotoxic activity (EC50) of the anti-CD7 ADC on T cell acute leukaemia (T-ALL) cells Jurkat and KOPT-K1 was found to be in the range of 5-8 ng/mL. In a pre-clinical xenograft model of human tumour growth expressing CD7 antigen, growth was curtailed by a single dose of ADC. The data indicate that CD7 targeting ADCs may be developed into an important second stage therapy for T cell acute leukaemia, for refractory CD7-positive leukaemias and for subsets of acute myeloid leukaemia (AML) expressing CD7.

Human beta-defensin 2 and beta-defensin 3 chimeric peptides reveal the structural basis of the pathogen specificity of their parent molecules.

Despite partial sequence identity and structural similarity, human ß-defensin 3 (HBD3) kills Staphylococcus aureus with a 4- to 8-fold higher efficiency than human ß-defensin 2 (HBD2), whereas the activities against Escherichia coli are identical. The design and characterization of HBD2/HBD3 chimeric peptides revealed that distinct molecular regions are responsible for their divergent killing properties. Two of the chimeras killed both E. coli and S. aureus with an even higher efficacy than the wild-type molecules. Moreover, one of these two chimeras maintained its high killing activities in the presence of physiologic salt concentrations. Due to the broad spectrum of their antimicrobial activities against many human multidrug-resistant pathogens, these two designer peptides of human origin represent promising templates for a new class of antibiotics.

Caenopore-5: the three-dimensional structure of an antimicrobial protein from Caenorhabditis elegans.

The caenopore-5 protein encoded by the spp-5 gene is one of the 33 caenopores identified in Caenorhabditis elegans and is a pore-forming peptide which plays an important role in the elimination of Escherichia coli ingested by the worm. Thus, caenopore-5 appears to contribute to the nutrition of the worm while simultaneously protecting the organism against pathogens. Here, three-dimensional heteronuclear NMR spectroscopy was used to solve the solution structure of caenopore-5. The NMR data revealed that two conformers of caenopore-5 exist in solution which differ by the isomerization of the peptide bond of Pro-81. The overall structure of the two caenopore-5 conformers consists of five amphiphatic helices connected by three disulfide bonds. The five helices are arranged in a folded leaf which is the characteristic signature of the SAPLIP family. The structure presented here is the first of an effector protein of the defensive system elucidated for the well-known model organism C. elegans.

Designing point mutants to detect structural coupling in a heterotrimeric G protein alpha-subunit by NMR spectroscopy.

To better understand the mechanism by which the activating signal is transmitted from the receptor-interacting regions on the G protein alpha-subunit (G(alpha)) to the guanine nucleotide-binding pocket, we generated and characterized mutant forms of G(alpha) with alterations in switch II (Trp-207-->Phe) and the carboxyl-terminus (Phe-350-->Ala). Previously reported bacterial expression methods for the high-level production of a uniformly isotope-labeled G(talpha)/G(i1alpha) chimera, ChiT, were successfully used to isolate milligram quantities of (15)N-labeled mutant protein. NMR analysis showed that while the GDP/Mg(2+)-bound state of both mutants shared an overall conformation similar to that of the GDP/Mg(2+)-bound state of ChiT, formation of the "transition/activated" state in the presence of aluminum fluoride (AlF(4) (-)) revealed distinct differences between the wild-type and mutant G(alpha) subunits, particularly in the response of the (1)HN, (15)N cross-peak for the Trp-254 indole in the Trp-207-->Phe mutant and the (1)HN, (15)N cross-peak for Ala-350 in the Phe-350-->Ala mutant. Consistent with the NMR data, the F350-->Ala mutant showed an increase in intrinsic fluorescence that was similar to G(talpha) and ChiT upon formation of the "transition/activated" state in the presence of AlF(4) (-), whereas the intrinsic fluorescence of the Trp-207-->Phe mutant decreased. These results show that the substitution of key amino acid positions in G(alpha) can effect structural changes that may compromise receptor interactions and GDP/GTP exchange.

Structural characterization and binding properties of the hemopexin-like domain of the matrixmetalloproteinase-19.

The matrixmetalloproteinase-19 (MMP-19) belongs to the superfamily of the zinc-dependent endopeptidases, which are secreted by cells and are involved in the remodeling of the extracellular matrix. The full-length protein consists of a signal peptide, a propeptide, a catalytic domain and a C-terminal hemopexin-like domain. For other members of this superfamily, the hemopexin-like domain has been described to be involved in substrate recognition. In this study, the hemoxpexin domain of MMP-19 was expressed in Escherichia coli, refolded, and purified. For structural characterization, circular dichroism and NMR spectroscopy were used. We show that the hemopexin-like domain of MMP-19 is able to bind calcium and this binding induces a conformational change and an increase in the thermal stability of the domain. MMP-19 promotes proliferation of keratinocytes by cleaving the insulin-like-growth factor binding protein-3, thereby causing the release of IGF-1, which is a potent growth factor for these cells. By plasmon resonance experiments, we show that the isolated hemopexin-like domain is able to bind to the insulin-like-growth factor binding protein-3. These results provide a basis for further structural investigations that could be used for the rational design of potential agonists and antagonists.